Rheumatoid Arthritis Diagnostic Tests Market

Biomarker Testing is the fastest growing segment fueling the growth of Rheumatoid Arthritis Diagnostic Tests Market

by

The global Rheumatoid Arthritis Diagnostic Tests Market is estimated to be valued at US$ 2,775.1 Mn or Billion in 2023 and is expected to exhibit a CAGR of 5.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Rheumatoid arthritis diagnostic tests help in early detection and diagnosis of rheumatoid arthritis. These tests include rheumatoid factor testing, anti-CCP antibody testing and biomarker testing. Biomarker testing includes evaluation of levels of inflammatory proteins like cytokines and acute phase proteins which indicate the state of inflammation.

Market key trends:

One of the key trends in the rheumatoid arthritis diagnostic tests market is the rise in demand for biomarker testing. Biomarkers are cellular, biochemical or molecular alterations that are measurable indicators of normal biological and pathogenic processes. Biomarker testing helps in early diagnosis, prognosis and monitoring treatment efficacy in rheumatoid arthritis. Levels of various biomarkers like matrix metalloproteinases, cytokines like interleukin-6 and tumor necrosis factor- help determine disease activity and predict response to therapy. With the growing emphasis on precision medicine, biomarkers are considered an attractive tool in rheumatoid arthritis management.

Segment Analysis:-

The global rheumatoid arthritis diagnostic tests market is segmented based on test type and end user. By test type, the market is segmented into serology tests, rheumatoid factor (RF) tests, anti-CCP tests, erythrocyte sedimentation rate (ESR) tests, and imaging tests. The serology tests segment is expected to dominate the market during the forecast period owing to the high sensitivity and specificity provided by these tests in diagnosis of RA.

Key Takeaways:-

The Global Rheumatoid Arthritis Diagnostic Tests Market Demand is expected to witness high growth, exhibiting a CAGR of 5.4% over the forecast period, due to increasing geriatric population suffering from rheumatoid arthritis.

The market size for 2023 is US$ 2,775.1 Mn. North America is expected to dominate the global market during the forecast period owing to supportive government initiatives and presence of major players in the region.

Regional analysis:-

North America is expected to command the largest share in the global rheumatoid arthritis diagnostic tests market during the forecast period. Factors such as increasing prevalence of rheumatoid arthritis, huge healthcare expenditure, and availability of advanced healthcare facilities are expected to drive the market in the region.

Key players:-

Key players operating in the rheumatoid arthritis diagnostic tests market are Abbott Diagnostics (Abbott Laboratories), Labcorp, Antibodies Inc., Networks LLC, Beckman Coulter, Inc., Euro Diagnostica AB, F. Hoffmann-La Roche Ltd., Qiagen NV, Siemens Healthcare GmbH, Augurex Life Sciences Corp., Thermo Fisher Scientific Inc., Bio Rad Laboratories Inc., Exagen Inc., Genway Biotech, Inc., Microdrop LLC (imaware), Svar Life Science AB, and Thermo Fisher Scientific Inc.

*Note:
1.  Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it